|

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

RECRUITINGSponsored by Kyowa Kirin, Inc.
Actively Recruiting
SponsorKyowa Kirin, Inc.
Started2019-09-10
Est. completion2030-02
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04014374

Summary

This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
* Adults ≥18 years of age with either CTCL or ATLL;
* AlloHCT performed from January 2012 onward.

Exclusion Criteria:

• Patients without consent for research.

Conditions4

ATLLCancerCutaneous T Cell LymphomaLeukemia/Lymphoma

Locations1 site

CIBMTR
Milwaukee, Wisconsin, 53226

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.